Market Vectors® Pharmaceutical ETF
Latest Market Vectors® Pharmaceutical ETF News and Updates
Earnings ReportNovartis’s 2Q17 Earnings: Analyst Estimates
Novartis is set to release its 2Q17 earnings on July 18, 2017. Analysts estimate EPS (earnings per share) of $1.18 and revenues of $12.3 billion. Company & Industry OverviewsFarxiga Could See Robust Demand in International Markets in 2017
In 1Q17, AstraZeneca’s (AZN) Farxiga reported sales of $42 million in emerging markets, which equals year-over-year growth of ~100% on a reported basis. Company & Industry OverviewsWhat We Can Expect from Eli Lilly and Company in 2Q17
A look at Eli Lilly and Company Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a US pharmaceutical company focused on human pharmaceuticals and animal health. Stock price performance Eli Lilly’s stock price has fallen ~4.4% in 2Q17. However, the stock price had risen 10.9% year-to-date as of July 7, 2017. Analysts’ recommendations Wall […] Company & Industry OverviewsKeytruda’s Developments in June 2017
On June 12, 2017, Merck released updated data for Keytruda’s two phase III studies—KEYNOTE-183 and KEYNOTE-185—which evaluate Keytruda in combination with other drugs for the treatment of multiple myeloma. Company & Industry OverviewsPfizer’s Profitability in 1Q17
Pfizer’s gross margin for 1Q17 was 81.0%, a 0.70% rise compared to 80.3% in 1Q16. Company & Industry OverviewsAnalyzing Bristol-Myers Squibb’s Valuation on June 20
As of June 20, 2017, Bristol-Myers Squibb was trading at a forward PE multiple of ~18.0x—compared to the industry average of 16.0x. Company & Industry OverviewsSK Biotek to Acquire Manufacturing Facility in Swords, Ireland
In its press release on June 16, 2017, Bristol-Myers Squibb (BMY) announced that it entered into a definitive purchase agreement with SK Biotek. Company & Industry OverviewsWhat Drove Pfizer in 1Q17?
Growth drivers for Pfizer (PFE) include products contributing to operational growth, such as BMP2, Celebrex, Ibrance, Lyrica, and Xeljanz. Company & Industry OverviewsInside Novartis’s Generics Business Now
Sandoz is also a leader in differentiated generics. Its contribution made up ~21% of Novartis’s total revenues in 1Q17. Company & Industry OverviewsGardasil and Merck’s Vaccines Business in 1Q17
Gardasil is Merck’s (MRK) leading vaccine franchise. Total sales for Gardasil in 1Q17 were $532.0 million, a ~41.0% rise over $378.0 million in 1Q16. Earnings ReportDupixent Expected to Be a Solid Addition to Regeneron’s Portfolio
On March 28, 2017, the FDA approved Regeneron (REGN) and Sanofi’s (SNY) Dupixent for the treatment of patients with moderate-to-severe eczema or atopic dermatitis (or AD). Company & Industry OverviewsCosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe
In 2016, Novartis’s (NVS) Cosentyx surpassed its closest competitor, Eli Lilly’s (LLY) Taltz, in number of total weekly prescriptions in the US market. Company & Industry OverviewsEmerging Markets Expected to Be AstraZeneca’s Key Growth Driver
For 2016, AstraZeneca (AZN) reported revenues of about $5.8 billion for its emerging markets business, which is a YoY (year-over-year) rise of about 6.0%. Company & Industry OverviewsTeva Is Well Positioned for New Trends in the US Generic Market
Because of its drug portfolio, manufacturing operations, and customer relationships, Teva expects to benefit from new trends in the US generic market. Company & Industry Overviews2016’s Estimated Product Launches: LixiLan, Sarilumab, Lixisenatide
LixiLan indicated for type 2 diabetes is a combination of Lantus and lixisenatide. Lantus is Sanofi’s most frequently prescribed diabetes drug. Company & Industry OverviewsPfizer’s Hospira Deal: Catching Up a Year Later
On September 13, 2015, Pfizer (PFE) completed its acquisition of Hospira for $17 billion. Company & Industry OverviewsUnderstanding Sanofi’s Strategic Priority
As of June 30, 2016, the animal health business was Sanofi’s operating segment. It will remain an operating segment until the transaction closes. Company & Industry OverviewsWhy Are Revenues from Pfizer’s Rare Disease Portfolio Falling?
BeneFIX, the major contributor to Pfizer’s (PFE) Rare Disease portfolio, is indicated for hemophilia B. During the first six months, the drug earned $367 million. Company & Industry OverviewsWhy Pfizer’s Enbrel Faces a Sales Decline
Wall Street analysts expect Enbrel to earn $3 billion and $2.5 billion from the sale outside US and Canada in fiscal 2016 and 2017, respectively. Company & Industry OverviewsThe Facts behind the Valeant Drug Pricing Controversy
Valeant Pharmaceuticals International (VRX) significantly raised the prices of two of its heart drugs—Nitropress and Isuprel—which caused a controversy and an outrage. Company & Industry OverviewsWhat’s Novartis’s New Structure?
Novartis (NVS) has restructured its entire business into two parts: continuing operations and discontinuing operations. Company & Industry OverviewsWhat Risks Does Novartis Face?
Novartis is exposed to legal risks, including patent litigations, other product-related litigation, commercial litigation, government investigations, and prohibition rules. Company & Industry OverviewsWhich Products Contribute the Most to Novartis’s Revenues?
Novartis (NVS) has recorded direct product sales of over $1 billion for each of its ten pharmaceutical products in the last year. Earnings ReportWhat’s behind Valeant’s Operating Expenses?
Valeant’s major operating expenses include cost of sales, SG&A (selling, general, and administrative) expenses, and R&D (research and development) costs. Company & Industry OverviewsWhat’s Happening with a Generic Version of Vyvanse?
Vyvanse, Shire’s (SHPH) key drug, earned $1.7 billion in 2015, a 21% annual growth. Analysts expect Vyvanse to add $1.9 billion and $2.1 billion to Shire’s top line in 2016 and 2017. Earnings ReportWhat Are Novartis’s Valuation Multiples?
Based on the last five-year multiple range of ~9x to ~20x, Novartis’s current valuation is neither high nor low. Company & Industry OverviewsAbbVie’s Therapies in Virology, Neurology, and Women’s Health
In addition to its Oncology and Immunology segments, AbbVie is focused on launching innovative therapies in its Virology, Neurology, and Women’s Health segments. Company & Industry OverviewsNovo Nordisk’s Innovative Research and Development Pipeline
Novo Nordisk’s research and development pipeline includes three late-stage insulin studies of faster-acting insulin aspart, semaglutide, and LATIN T1D. Company & Industry OverviewsNovo Nordisk Plans to Pursue Leadership in Hemophilia Market
Novo Nordisk is pursuing leadership in the hemophilia market with its new drugs as well as a few investigational hemophilia drugs in its late-stage research pipeline. Company & Industry OverviewsNovo Nordisk’s Business Model: An Overview
Novo Nordisk’s (NVO) business model includes a portfolio in areas such as diabetes, hemophilia, and growth hormones. In the first half of 2015, diabetes care accounted for 78.6% of its total revenues. Company & Industry OverviewsNovo Nordisk: An Investor’s Guide to a Leading Biotech Company
Novo Nordisk (NVO) is a leader in diabetes care with 90 years of experience coupled with a strong workforce of 39,700 in 75 countries around the world. Company & Industry OverviewsAbbVie’s Endocrinology, Cardiovascular, and Rare Disease Segments
AbbVie has a diversified offering of drugs for the treatment of conditions related to endocrinology, cardiovascular, and rare disease. Company & Industry OverviewsAbbVie Has a Strong Metabolic and Hormonal Portfolio
AbbVie’s metabolic and hormonal portfolio offers drugs such as AndroGel, Creon, and Synthroid to address various medical conditions. Company & Industry OverviewsHumira Continues to Dominate AbbVie’s Revenues
Since Humira’s launch in the US market in 2002, Abbott Laboratories and its spin-off AbbVie have aggressively expanded the drug’s approved indications. Company & Industry OverviewsAn Overview of AbbVie’s Business Model
AbbVie’s business model involves generating revenues through the sale of pharmaceutical products, which target some of the world’s most serious diseases. Company & Industry OverviewsAbbVie: An Investor’s Look at a Leading Biotechnology Company
With a market capitalization of $100.7 billion, AbbVie is a major US biopharmaceutical company. AbbVie competes with Amgen, Gilead Sciences, and Bristol-Myers Squibb .